TwinStrand DuplexSeq measuring MRD in AML

Highest Resolution Next-Generation Sequencing (NGS)

TwinStrand Duplex Sequencing® technology reduces your sequencing error rates from 1-in-100 to 1-in-10 million, revealing data otherwise hidden. Using a combination of proprietary biochemistry and cloud-based informatics, the limitations of standard sequencing are overcome by independently tracking both strands of individual DNA molecules and comparing the results to eliminate errors.

Detect Rare Variants Like Never Before

Whether you are studying measurable residual disease, mutation signatures, cellular immunotherapy monitoring, or any low-level variants, you need accuracy beyond standard NGS. TwinStrand Duplex Sequencing reveals important low frequency variants that aren’t detectable by other methods. Get started with an off-the-shelf kit, or collaborate with us on a custom kit for your specific needs.

In The Spotlight

Duplex Sequencing identifies genomic features that determine susceptibility to benzo(a)pyrene-induced in vivo mutations

Researchers from Health Canada recently published a paper revealing a positive correlation between Duplex Sequencing (DS) technology and the current “gold-standard” transgenic rodent (TGR) assay to assess mutagenicity. The inter-laboratory validation study indicated consistent results across laboratories (Health Canada and TwinStrand Biosciences). The findings in this study show that DS yields novel insights into the mutagenic mode of action, which may help to overcome limitations of current mutagenicity assays for future regulatory decision making.

Put Duplex Sequencing to work for you.

To get started, click “contact us” below to tell us about your current work and to learn how our Duplex Sequencing technology will revolutionize your research.